From: Thyroid autoimmunity and IVF/ICSI outcomes in euthyroid women: a systematic review and meta-analysis
Outcome | Unadjusted OR / SMD (95% CI) | P value | I2 | Studies Excluded Following Sensitivity Analysis | OR (95% CI) Following Exclusion of Studies due to Sensitivity Analysis | P value | I2 |
---|---|---|---|---|---|---|---|
CPR - overall | OR 0.86; 95%CI [0.70, 1.05] | 0.14 | 29% | Â | Â | Â | Â |
CPR - euthyroid | OR 0.88; 95%CI [0.69, 1.12]; | 0.29 | 32% | Â | Â | Â | Â |
CMR – overall | OR 1.04; 95%CI [0.52, 2.07] | 0.908 | 53% | Poppe 2003 | OR 0.74; 95%CI [0.46, 1.19) | 0.21 | 0.00% |
CMR – euthyroid | OR 1.18; 95%CI [0.52, 2.64] | 0.69 | 54% | Poppe 2003 | OR 0.81; 95%CI [0.46, 1.41] | 0.45 | 0.00% |
BPL- overall | OR 1.14; 95%CI [0.48, 2.72] | 0.769 | 0% | Â | Â | Â | Â |
BPL- euthyroid | - | Â | Â | Â | Â | Â | Â |
MR - overall | OR 1.33; 95%CI [0.83, 2.15] | 0.23 | 47% | Â | Â | Â | Â |
MR - euthyroid | OR 1.26; 95%CI [0.72–2.18] | 0.42 | 35% |  |  |  |  |
LBR/CP - overall | OR 0.67; 95%CI [0.28, 1.60] | 0.37 | 69% | Poppe 2003 | OR 0.92; 95%CI [0.57, 1.48] | 0.722 | 0.00% |
LBR/CP - euthyroid | – |  |  |  |  |  |  |
LBR/cycle - overall | OR 0.84; 95%CI [0.67, 1.06] | 0.15 | 2% | Â | Â | Â | Â |
LBR/cycle – euthyroid | - |  |  |  |  |  |  |
ET - overall | SMD 0.02; 95%CI [−0.18, 0.22] | 0.85 | 69% | Chen 2017 | SMD 0.13; 95%CI [−0.00, 0.26] | 0.054 | 0.00% |
ET - euthyroid | SMD 0.07; 95%CI [− 0.13, 0.2] | 0.49 | 0% |  |  |  |  |
NOR – overall | SMD −0.07; 95%CI [− 0.20, 0.06] | 0.27 | 49% |  |  |  |  |
NOR - euthyroid | SMD −0.05; 95%CI [− 0.25, 0.16] | 0.67 | 60% | Karacan 2013 | SMD −0.14; 95%CI [− 0.30, 0.02] | 0.08 | 26% |
Age - overall | SMD 0.12; 95%CI [−0.04, 0.28] | 0.15 | 76% |  |  |  |  |
Age - euthyroid | SMD 0.13; 95%CI [−0.10, 0.36] | 0.25 | 82% |  |  |  |  |
TSH - overall | SMD 0.28; 95%CI [−0.03, 0.59] | 0.08 | 79% |  |  |  |  |
TSH – euthyroid | SMD 0.14; 95%CI [−0.07, 0.34] | 0.19 | 46% |  |  |  |  |